IP Library Granted Patent US 7,151,095
Granted Patent B2
US 7,151,095 · App. 10/967,736 · Granted Dec 19, 2006

Immunoregulatory compounds and derivatives and methods of treating diseases therewith

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,151,095
App. No.
10/967,736
Granted
Dec 19, 2006
Kind
B2
Abstract

Compounds are disclosed having the structure of Formula I: where R 1 , R 3 , and R 4 are independently hydrogen or C 1 to C 4 alkyl, and R 2 is: where R 5 is selected from the group consisting of hydrogen and C 1 to C 4 alkyl, or where R 6 , R 7 and R 8 are independently hydrogen or C 1 to C 4 alkyl; or the esters or pharmacologically acceptable salts thereof. Such compounds may be utilized for the prophylaxis or treatment of various diseases, particularly inflammatory conditions of the GI tract. Methods of treating inflammatory conditions of the GI tract such as inflammatory bowel disease using compounds having the following formula are also disclosed: where R 9 , R 10 and R 11 are independently selected from the group consisting of hydrogen and C 1 to C 4 alkyl, and R 12 is selected from the group consisting of hydrogen and —C(O)R 13 , where R 13 is a C 1 to C 6 alkyl or an aryl group.

Claims (20)

1. A method of treating an inflammatory condition of the gastrointestinal tract in a subject in need of such treatment comprising administering to the subject a pharmaceutical composition comprising an active pharmaceutical ingredient consisting essentially of a compound of Formula II:

where R 9 ,R 10 and R 11 are independently selected from the group consisting of hydrogen and C 1 to C 4 alkyl; and

R 12 is selected from the group consisting of hydrogen and —C(O)R 13 , where R 13 is a C 1 to C 6 alkyl or an aryl group;

or an ester or a pharmaceutically acceptable salt of such compound, in admixture with pharmaceutical diluent or carrier.

2. The method according to claim 1 , wherein R 9 ,and R 10 , and R 11 are independently selected from the group consisting of H, CH 3 , CH 2 CH 3 , and CH(CH 3 ) 2 .

3. The method according to claim 1 , wherein R 9 , R 10 , and R 11 are independently selected from the group consisting of H and CH 3 .

4. The method according to claim 1 , wherein R 12 is hydrogen.

5. The method according to claim 1 , wherein the compound of Formula II is 4-aminophenylacetic acid.

6. The method according to claim 1 , wherein the inflammatory condition of the gastrointestinal tract is ulcerative colitis.

7. The method according to claim 1 , wherein the inflammatory condition of the gastrointestinal tract is Crohn's disease.

8. The method according to claim 1 , wherein the administering comprises orally administering to a subject in need of such treatment an effective amount of the active pharmaceutical ingredient.

9. The method according to claim 1 , wherein the administering comprises rectally administering to a subject in need of such treatment an effective amount of the active pharmaceutical ingredient.

10. A method of treating an inflammatory condition of the gastrointestinal tract in a subject in need of such treatment comprising administering to the subject the following compounds (a) 4-aminophenylacetic acid and/or esters or pharmaceutically acceptable salts thereof and (b) 5-aminosalicylic acid and/or esters or pharmaceutically acceptable salts thereof.

11. The method according to claim 10 , wherein the inflammatory condition of the gastrointestinal tract is ulcerative colitis.

12. The method according to claim 10 , wherein the inflammatory condition of the gastrointestinal tract is Crohn's disease.

13. The method according to claim 10 , wherein the administering comprises orally administering to the subject an effective amount of the compounds.

14. The method according to claim 10 , wherein the administering of an effective amount of the active pharmaceutical ingredient comprises rectally administering to the subject an effective amount of the compounds.

15. A compound having the following structure:

16. A compound having the following structure:

17. A compound having the following structure:

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE INVENTOR'S EXECUTION DATE PREVIOUSLY RECORDED AT REEL: 015606 FRAME: 0261. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded May 20, 2019
From: EKWURIBE, NNOCHIRI N.; RIGGS-SAUTHIER, JENNIFER
To: NOBEX CORPORATION
Reel/Frame 049236/0110 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2006
From: NOBEX CORPORATION
To: BIOCON LIMITED
Reel/Frame 017555/0904 →
SECURITY AGREEMENT Recorded Mar 9, 2006
From: NOBEX CORPORATION
To: BIOCON LIMITED
Reel/Frame 017649/0280 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2005
From: EKWURIBE, NNOCHIRI N.; RIGGS-SAUTHIER, JENNIFER
To: CORPORATION, NOBEX
Reel/Frame 015606/0261 →